Tango Therapeutics TNGX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$45.51M-14.1% | -$38.75M-2.9% | $15.88M+154% | -$38.85M-52.1% | -$39.88M-5.2% | ||
| $463K-25.6% | $479K-22.7% | $555K-10.8% | $625K-1.1% | $622K-0.5% | ||
| $10.8M+48.8% | $5.98M-19.9% | $6.63M-7.7% | $6.57M-12.8% | $7.26M+8.0% | ||
| $1.79M+9.5% | -$1.23M+50.9% | —— | —— | $1.63M+56.4% | ||
| -$10K-900% | $13K+244% | $0— | $307K+30,800% | -$1K+97.1% | ||
| -$21K-138% | $19K— | $1K— | $1K+102% | $56K+460% | ||
| —— | $0+100% | -$53.81M-364% | -$3.18M+59.1% | -$5.39M+16.7% | ||
| $972K-4.0% | $958K+0.4% | $973K+3.4% | $1.02M+10.1% | $1.01M+9.4% | ||
| -$44.36M-6.4% | -$29.72M+18.9% | -$30.95M+7.3% | -$36.52M-54.7% | -$41.7M-10.1% | ||
| -$2K-104% | $222K+79.0% | $151K+31.3% | $624K+95.0% | $51K-73.8% | ||
| $9.64M-68.5% | -$135.72M-361% | $47.48M+45.8% | $16.78M+32.1% | $30.6M+373% | ||
| $17.61M+880,150% | —— | —— | —— | $2K-100.0% | ||
| $79.85M+3,992,200% | $219.38M+22,539% | $2.54M+5.8% | $581K-55.7% | $2K-100.0% | ||
| $45.12M+507% | $53.94M+229% | $19.07M+1,105% | -$19.16M-99.6% | -$11.1M-82.6% | ||
| $463K-25.6% | $479K-22.7% | $555K-10.8% | $625K-1.1% | $622K-0.5% | ||
| $1.79M+9.5% | -$1.23M+50.9% | —— | —— | $1.63M+56.4% | ||
| -$8.69M-41.9% | $4.49M+201% | —— | —— | -$6.12M-281% | ||
| —— | $0+100% | -$53.81M-364% | -$3.18M+59.1% | -$5.39M+16.7% | ||
| -$781K-0.1% | -$1.19M-5.2% | -$245K-16.7% | -$814K-33.9% | -$780K-315% | ||
| $2.3M+454% | —— | $1.65M— | $1.11M+152% | -$649K-80.3% | ||
| $972K-4.0% | $958K+0.4% | $973K+3.4% | $1.02M+10.1% | $1.01M+9.4% | ||
| -$21K-138% | $19K— | $1K— | $1K+102% | $56K+460% | ||
| $537K+5,867% | $9K— | $9K— | $9K— | $9K— | ||
| —— | —— | —— | —— | —— | ||
| $17.61M+880,150% | —— | —— | —— | $2K— | ||
| —— | —— | —— | $248K+449% | $8K-88.7% | ||
| —— | —— | —— | —— | $1.31M+2,391% | ||
| —— | —— | —— | $1.12M— | $75K-84.9% | ||
| $1.45M-25.2% | $1.46M-21.9% | $468K-67.0% | $1.99M+107% | $1.94M+43.2% | ||
| -$44.36M-6.3% | -$29.94M+18.6% | -$31.1M+7.2% | -$37.14M-55.2% | -$41.75M-9.7% | ||
| -$44.36M-6.3% | -$29.94M+18.6% | -$31.1M+7.2% | -$37.14M-55.2% | -$41.75M-9.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Tango Therapeutics's cash flow data come from?
- Every line is extracted from Tango Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.